CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
CLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...
Read More
Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit
CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...
Read More
Dividend/Distribution – CUV
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4E & Annual Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
CLINUVEL Communiqué IV
Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
PRÉNUMBRA® for stroke
Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
CLINUVEL Kommuniqué III
Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More